Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light

Transfusion and Apheresis Science

Volumn 37, Issue 2, 2007, Pages 131-137

  Cardo, Lisa J ^a   Salata, Jeanne ^a   Mendez, Juan ^a   Reddy, Heather ^b   Goodrich, Raymond ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Navigant Biotechnologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT; RIBOFLAVIN; THROMBOCYTE CONCENTRATE;

ARTICLE; BACTERIAL VIRULENCE; IMMUNE DEFICIENCY; TRYPANOSOMA CRUZI; ULTRAVIOLET RADIATION;

ANIMALS; BLOOD COMPONENT REMOVAL; BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; CHAGAS DISEASE; DISINFECTION; HUMANS; PLASMA; REFERENCE VALUES; RIBOFLAVIN; SENSITIVITY AND SPECIFICITY; TRYPANOSOMA CRUZI; ULTRAVIOLET RAYS;

EID: 36549038538     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.07.002     Document Type: Article

References (30)

1. Kirchhoff L.V. American trypanosomiasis (Chagas' disease): a tropical disease now in the United States. NEJM 329 (1993) 639-644
2. Schmunis G.A. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supplying endemic and non-endemic countries. Transfusion 31 (1995) 347-557
3. World Health Organization: control of Chagas disease: Second report of a WHO expert committee. WHO Tech Pep Series 2002; 905:1-09.
4. Grant I.H., Gold J.V.V.M., Wittner M., Tanowitz H.B., Nathan C., Mayer K., et al. Transfusion-associated acute Chagas' disease acquired in the United States. Ann Intern Med 111 (1989) 849-851
5. Nickerson P., Orr P., Schroeder M.L., Sekla L., and Johnston J.B. Transfusion-associated Trypanosoma cruzi infection in a non-endemic area. Ann Intern Med 111 (1989) 851-853
6. Cimo P.L., Luper W.E., and Scouros M.A. Transfusion-associated Chagas' disease in Texas: report of a case. Tex Med 89 (1993) 48-50
7. Leiby D.A., Herron R.M., Read E.J., Lenes B.A., and Stumpf R.J. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving door demographics on seroprevalence and implications for transfusion transmission. Transfusion 42 (2002) 549-555
8. Kirchhoff L.V., Paredes P., Lomeli-Guerrero A., Pareses-Espinoza M., Ron-Guerrero C.S., Delgado-Mejia M., et al. Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 46 (2006) 298-304
9. Leiby D.A. Threats to blood safety posed by emerging protozoan pathogens. Vox Sang 87 Suppl. 2 (2004) S120-S122
10. Decmapo R., Morenao S.N., Gadelha F.R., de Souza W., and Cruz F.S. Prevention of Chagas' disease resulting from blood transfusion by treatment of blood: toxicity and mode of action of gentian violet. Biomed Environ Sci 1 (1998) 406-413
11. Gadelha F.R., Moreno S.N., de Souza W., Cruz F.S., and Decampo R. The mitochondrion of Trypanosoma cruzi is a target of crystal violet toxicity. Mol Biochem Parasitol 34 (1989) 117-126
12. Zavizon B., Pereira M., de Melo J.M., Serebryanik D., Mather T.N., Chapman J., et al. Inacativation of protozoan parasites in red blood cells using INACTINE PEN 110 chemistry. Transfusion 44 (2004) 731-738
13. Gutierrez-Correa J., Krauth-Siegel R.L., and Stoppani A.O. Phenothiazine radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase: enzyme protection by radical scavengers. Free Radical Res 37 (2003) 281-291
14. Van Voorhis W.C., Barrett L.K., Eastman R.T., Alfonso R., and Dupuis K. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 47 (2003) 475-479
15. Gutierrez-Correa J., Krauth-Siegel R.L., and Stoppani A.O. Inactivation of Trypanosoma cruzi dihydrolipoamide dehydrogenase by leukocyte myeloperoxidase systems: role of hypochloride and nitrite radicals. Rev Argent Microbiol 32 (2000) 136-143
16. Ben-Hur E., Chan W.S., Yim Z., Zuk M.M., Dayal V., Roth N., et al. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light. Dev Biol (Basel) 102 (2000) 149-155
17. Moraes-Souza H., Bordin J.O., Bardossy L., MacPherson D.W., and Blajchman M. Prevention of transfusion-associated Chagas' disease: efficacy of white cell-reduction filters in removing Trypanosoma cruzi from infected blood. Transfusion 35 (1995) 723-726
18. Zempleni J., Galloway J.R., and McCormick D.B. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 63 (1996) 54-66
19. Unna K., and Greslin J. Studies on the toxicity and pharmacology of riboflavin. J Pharmacol Exp Ther 75 (1942) 75-80
20. - production by riboflavin, lumichrome and lumiflavin. Indian J Biochem Biophys 26 (1989) 186-189
21. Goodrich R.P. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 78 Suppl 2 (2000) 211-215
22. Perez-Pujol S., Tonda R., Lozano T.M., Fuste B., Lopez-Vilchez I., Galan A.M., et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 45 (2005) 911-919
23. Ruane P.H., Edrich R., Gampp D., Keil S.D., Leonard R L., and Goodrich R.P. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 44 (2004) 855-877
24. AuBuchon J.P., Herschel L., Roger J., Taylor H., Whitley P., Li J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 45 (2005) 1335-1341
25. Li J., de Korte D., Woolum M.D., Ruane P.H., Keil S.D., Lockerbie O., et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 87 (2004) 82-9021
26. Li J., Lockerbie O., de Korte D., Rice J., McLean R., and Goodrich R.P. Evaluation of platelet mitochondria integrity after treatment with mirasol pathogen reduction technology. Transfusion 45 (2005) 920-926
27. Cardo L.J., Rentas F.J., Ketchum L., Salata J., Harman R., Melvin W., et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 90 (2006) 85-91
28. Lippert L., Watson R., Doane S., Reddy H., and Goodrich R. Inactivation of P. falciparum by riboflavin and light. Vox Sang 83 Suppl. 2 (2002) 163
29. Kreutzer R.D., and Christensen H.A. Characterization of leishmania spp. by isoenzyme electrophoresis. Am J Trop Med Hyg 29 (1980) 199-208
30. Kirchhoff L.V., and Neva F.A. Chagas' disease in Latin American immigrants. JAMA 254 (1985) 3058-3060